Hematology

Offline Online
My videos
Incorporating Different Schedules into Combinations Use minimum active dose

Incorporating Different Schedules into Combinations Use ...
Ruben Niesvizky, MD, explains Incorporating Different Schedules into Combinations Use minimum active dose at Imedex Great Debates 2018.
310 Views
4 years ago
Want to watch this again later?
Sign in to add this video to a playlist. Login
Quadruple Agents in Relapse Refractory Myeloma Capitalizing on synergy & lack of toxicities
Quadruple Agents in Relapse Refractory Myeloma Capitaliz...
261 Views
4 years ago
Hematology
Want to watch this again later?
Sign in to add this video to a playlist. Login
Adding to Lenalidomide to Make it Work Better Prednisone inhibitors, carfilzomib, and bortezomib
Adding to Lenalidomide to Make it Work Better Prednisone...
220 Views
4 years ago
Hematology
Want to watch this again later?
Sign in to add this video to a playlist. Login
One Size Does Not Fit All in Myeloma Clonal Tiding & Complex Heterogeneity
One Size Does Not Fit All in Myeloma Clonal Tiding & Co...
280 Views
4 years ago
Hematology
Want to watch this again later?
Sign in to add this video to a playlist. Login
Early Transplant Confers PFS Benefit, but Not Overall Stem cell transplant is an option
Early Transplant Confers PFS Benefit, but Not Overall St...
203 Views
4 years ago
Hematology
Want to watch this again later?
Sign in to add this video to a playlist. Login
Combinations with RVD Beyond Daratumumab Data with ixazomib, revlimid, & dexamethasone
Combinations with RVD Beyond Daratumumab Data with ixazo...
203 Views
4 years ago
Hematology
Want to watch this again later?
Sign in to add this video to a playlist. Login
RVD-Lite Mission Treating Over 50 Patients Regimen of Bortezomib, lenalidomide, steroids
RVD-Lite Mission Treating Over 50 Patients Regimen of Bor...
69 Views
4 years ago
Hematology
Want to watch this again later?
Sign in to add this video to a playlist. Login
Selinexor is a Novel Mechanism of Action Venetoclax Serves a Challenging Population
Selinexor is a Novel Mechanism of Action Venetoclax Serv...
167 Views
4 years ago
Hematology
Want to watch this again later?
Sign in to add this video to a playlist. Login
Role of Venetoclax in Plasma Cell Leukemia Excellent partner drug with non-overlapping toxicities
Role of Venetoclax in Plasma Cell Leukemia Excellent part...
129 Views
4 years ago
Hematology
Want to watch this again later?
Sign in to add this video to a playlist. Login
Powerful new IMiDs, CC-220 & CC-92480 Importance of Small Molecules in advanced trials
Powerful new IMiDs, CC-220 & CC-92480 Importance of Small...
284 Views
4 years ago
Hematology
Want to watch this again later?
Sign in to add this video to a playlist. Login
Melflufen is a Modified Derivative of Melphalan Peptidase-avid and a targeted form of chemotherapy
Melflufen is a Modified Derivative of Melphalan Peptidase...
247 Views
4 years ago
Hematology
Want to watch this again later?
Sign in to add this video to a playlist. Login
Selinexor is an Inhibitor of Nuclear Export Proteins Synergy with Bortezeomib on anti-myeloma activity
Selinexor is an Inhibitor of Nuclear Export Proteins Syn...
88 Views
4 years ago
Hematology
Want to watch this again later?
Sign in to add this video to a playlist. Login
Venetoclax Shown Great Results with Bortezomib It targets 11;14, oral, well-tolerated
Venetoclax Shown Great Results with Bortezomib It target...
88 Views
4 years ago
Hematology
Want to watch this again later?
Sign in to add this video to a playlist. Login
Control of disease can be achieved w Ibrutnib High-risk Relapsed Refractory patients will progress
Control of disease can be achieved w Ibrutnib High-risk...
62 Views
4 years ago
Hematology
Want to watch this again later?
Sign in to add this video to a playlist. Login
MBL Patients Dont Need Bone Marrow Biopsies MBL can be followed by CBCs and Physical Exams Early stage CLL and High-count MBL are similar
MBL Patients Dont Need Bone Marrow Biopsies MBL can be fo...
54 Views
4 years ago
Hematology
Want to watch this again later?
Sign in to add this video to a playlist. Login
4 New Drugs in the Treatment Landscape for AML Incorporating the new drugs in to AML management
4 New Drugs in the Treatment Landscape for AML Incorpora...
54 Views
4 years ago
Hematology
Want to watch this again later?
Sign in to add this video to a playlist. Login
Venetoclax Rapidly Moving as Best 2nd-line Therapy SCT still remains as the only curative treatment
Venetoclax Rapidly Moving as Best 2nd-line Therapy SCT s...
89 Views
4 years ago
Hematology
Want to watch this again later?
Sign in to add this video to a playlist. Login
Venetoclax w Rituximab progressed the furthest Phase 3 Data shows the combination is superior
Venetoclax w Rituximab progressed the furthest Phase 3 D...
45 Views
4 years ago
Hematology
Want to watch this again later?
Sign in to add this video to a playlist. Login
MBL Patients Dont Need Bone Marrow Biopsies MBL can be followed by CBCs and Physical Exams
MBL Patients Dont Need Bone Marrow Biopsies MBL can be fo...
54 Views
4 years ago
Hematology
Want to watch this again later?
Sign in to add this video to a playlist. Login
PET-Scans Not as Specific for Richters Transformation Biopsies are essential for those who fail new therapies
PET-Scans Not as Specific for Richters Transformation Bi...
45 Views
4 years ago
Hematology
Want to watch this again later?
Sign in to add this video to a playlist. Login
A lot of Questions on the Best Use of New Drugs Still waiting on more data, stick to the label
A lot of Questions on the Best Use of New Drugs Still wa...
71 Views
4 years ago
Hematology
Want to watch this again later?
Sign in to add this video to a playlist. Login
Role of Chimeric Antigen Receptor T Cells CAR-T Cell after multiple novel agent-based therapies
Role of Chimeric Antigen Receptor T Cells CAR-T Cell afte...
56 Views
4 years ago
Hematology
Want to watch this again later?
Sign in to add this video to a playlist. Login
Prognostics are difficult in the MBL population Del17P & NOTCH1 are relevant for time to treatment
Prognostics are difficult in the MBL population Del17P &...
56 Views
4 years ago
Hematology
Want to watch this again later?
Sign in to add this video to a playlist. Login
Enasidenib, an IDH2 Inhibitor based on Phase 1 Trial High-Response rate in patients with IDH2 mutation
Enasidenib, an IDH2 Inhibitor based on Phase 1 Trial Hig...
60 Views
4 years ago
Hematology
Want to watch this again later?
Sign in to add this video to a playlist. Login
Treatment of CLL Richters Transformations High Risk Patients will progress their disease
Treatment of CLL Richters Transformations High Risk Pat...
91 Views
4 years ago
Hematology
Want to watch this again later?
Sign in to add this video to a playlist. Login
Loading